Coverage with evidence development (CED)

In July 2023, the National Institute for Health and Disability Insurance (INAMI-RIZIV) significantly updated the process to obtain reimbursement for health apps. More stakeholders, including the industry, can now submit an application to INAMI-RIZIV for temporary or permanent reimbursement. The new process will come into force on October 1, 2023.

On March 8, 2023, the Ministry of Health and Prevention published an Order in the Official Journal of the French Republic on the coverage of the INTERVAPOR system for lung volume reduction under Forfait innovation program.

Rehabilitation before or after a primary knee or hip replacement using a health app is temporarily reimbursed in Belgium under a specific agreement with the National Institute for Health and Disability Insurance (INAMI-RIZIV). Reimbursement was limited to patients participating in the clinical study. From October 01, 2022, all patients eligible for rehabilitation before and after a primary knee or hip replacement will receive it using a health app in combination with a certain minimum number of classic face-to-face physiotherapy sessions. Certain health apps must be included in the list of reimbursable mobile applications. For now, only one app (MoveUP Coach) is included.

On June 22, 2022, the list of awarded PHRC and PRME projects, submitted in 2021, was published on the website of the French Ministry of Health and Prevention.

On June 22, 2022, the French Ministry of Health and Prevention published the instruction related to the 2022 application for coverage with evidence development programs. In the instruction, the specific fields of research, the application procedures, and the deadlines for applications for different types of projects (PHRC, PRME, PREPS, PHRIP, PRT) are specified.

On July 29, 2021, the French Ministry of Solidarity and Health published the instruction related to the 2021 application for coverage with evidence development programs. In the instruction, the specific fields of research, the application procedures, and the deadlines for applications for different types of projects (PHRC, PRME, PREPS, PRT) are specified.

On June 24, 2021, the list of awarded PHRC and PRME projects, submitted in 2020, was published. A total of 137 PHRC and nine PRME projects were awarded, and they concern various technology groups, such as gynecology, nephrology, neurology, cardiovascular, etc.

On July 1, 2021, the updated version of the Swiss Services Ordinance (KLV/OPre) came into force. The changes concern the List of explicitly evaluated services (Annex 1 of KLV/OPre), the List of medical aids (Annex 2 of KLV/OPre), and the List of Analyses (Annex 3 of KLV/OPre).

On February 5, 2021, the French Ministry of Solidarity and Health published the results of the pre-selection of applications submitted in 2020 for participating in the coverage with evidence development programs. Regarding the Health Economic Research Program (PRME), 20 applications regarding various medical technologies were selected, including high throughput genome sequencing analysis in pediatric diagnostics, robotic thoracic surgery during lobectomy or segmentectomy in lung cancer, robotic gastric bypass for morbid obesity, mechanical thrombectomy techniques in the treatment of ischemic stroke, CAR-T cell therapy in the treatment of diffuse large B-cell lymphomas, creation of arteriovenous accesses for hemodialysis - the surgical technique and the endovascular technique, etc. Regarding the national Hospital Program of Clinical Research (PHRC-N), 205 applications were pre-selected.

On December 22, 2020, the Swiss Federal Office of Public Health announced the changes that will occur to the Services Ordinance (KLV/OPre). The changes concern the general part of the Services Ordinance (KLV/OPre), and all four of its Annexes, which define the coverage of services (List of explicitly evaluated services, List of Medical Aids and Equipment, List of Analyses, List of Medications with Tariff). The updates will enter into force on January 1, 2021. Updates concern among others bariatric surgery, Autologous Chondrocyte Transplantation, ultrasound focused therapy for neurological indications.